Stereotactic Radiosurgery for Liver Lesions

  • Harun Badakhshi


Oligometastases of solid tumors to the liver might lead to severe functional affections and, in some cases, to fatal organ failure in patients (f/m) with liver lesions.

Invasive surgical procedures like partial hepatectomy performed seem to be the historic “standard.” Any “standard” has to prove its superiority in terms of safety and effectiveness for patients (f/m), and it is true in the frame of cost efficiency too.

Image-guided stereotactic radiosurgery with its multiple labels like stereotactic ablative radiotherapy (SABR) or stereotactic body radiotherapy (SBRT) could affect liver lesions by deactivating tumor cells. They are responsive to high-dose radiotherapy. Metastases, limited by volume, number, and occurrence site, react to radiation by stopping their growth. The aim would be the deactivation of lesions or, at least, to prolong the time free of hepatic symptoms and, therefore, to have a better quality of life.

Consecutively, it demonstrates a noninvasive high-precision and safe technique in treating patients (f/m).


Hepatic Metastasis Liver Lesion Metastatic Colorectal Cancer Stereotactic Body Radiotherapy Stereotactic Radiosurgery 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Wagner JS, Adson MA, Van Heerden JA, Adson MH, Ilstrup DM. The natural history of hepatic metastases from colorectal cancer. A comparison with resective treatment. Ann Surg. 1984;199(5):502–8.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Adson MA, van Heerden JA, Adson MH, Wagner JS, Ilstrup DM. Resection of hepatic metastases from colorectal cancer. Arch Surg. 1984;119(6):647–51.CrossRefPubMedGoogle Scholar
  3. 3.
    Fong Y, Kemeny N, Paty P, Blumgart LH, Cohen AM. Treatment of colorectal cancer: hepatic metastasis. Semin Surg Oncol. 1996;12(4):219–52.CrossRefPubMedGoogle Scholar
  4. 4.
    Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230(3):309–18; discussion 18–21.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Petrelli F, Coinu A, Zaniboni A, Pietrantonio F, Barni S. Prognostic factors after R0 resection of colorectal cancer liver metastases: a systematic review and pooled-analysis. Rev Recent Clin Trials. 2016;11(1):56–62.CrossRefPubMedGoogle Scholar
  6. 6.
    Phillips R, Karnofsky DA, Hamilton LD, Nickson JJ. Roentgen therapy of hepatic metastases. Am J Roentgenol Radium Ther Nucl Med. 1954;71(5):826–34.PubMedGoogle Scholar
  7. 7.
    Herfarth KK, Debus J, Lohr F, Bahner ML, Fritz P, Hoss A, et al. Extracranial stereotactic radiation therapy: set-up accuracy of patients treated for liver metastases. Int J Radiat Oncol Biol Phys. 2000;46(2):329–35.CrossRefPubMedGoogle Scholar
  8. 8.
    Herfarth KK, Debus J, Wannenmacher M. Stereotactic radiation therapy of liver metastases: update of the initial phase-I/II trial. Front Radiat Ther Oncol. 2004;38:100–5.CrossRefPubMedGoogle Scholar
  9. 9.
    Chang DT, Swaminath A, Kozak M, Weintraub J, Koong AC, Kim J, et al. Stereotactic body radiotherapy for colorectal liver metastases: a pooled analysis. Cancer. 2011;117(17):4060–9.CrossRefPubMedGoogle Scholar
  10. 10.
    Scorsetti M, Clerici E, Comito T. Stereotactic body radiation therapy for liver metastases. J Gastrointest Oncol. 2014;5(3):190–7.PubMedPubMedCentralGoogle Scholar
  11. 11.
    Aitken KL, Hawkins MA. Stereotactic body radiotherapy for liver metastases. Clin Oncol. 2015;27(5):307–15.CrossRefGoogle Scholar
  12. 12.
    Sterzing F, Brunner TB, Ernst I, Baus WW, Greve B, Herfarth K, et al. Stereotactic body radiotherapy for liver tumors: principles and practical guidelines of the DEGRO Working Group on Stereotactic Radiotherapy. Strahlentherapie und Onkologie Organ der Deutschen Rontgengesellschaft [et al]. 2014;190(10):872–81.CrossRefGoogle Scholar
  13. 13.
    Schefter TE, Kavanagh BD, Timmerman RD, Cardenes HR, Baron A, Gaspar LE. A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases. Int J Radiat Oncol Biol Phys. 2005;62(5):1371–8.CrossRefPubMedGoogle Scholar
  14. 14.
    Wulf J, Guckenberger M, Haedinger U, Oppitz U, Mueller G, Baier K, et al. Stereotactic radiotherapy of primary liver cancer and hepatic metastases. Acta Oncol. 2006;45(7):838–47.CrossRefPubMedGoogle Scholar
  15. 15.
    Katz AW, Carey-Sampson M, Muhs AG, Milano MT, Schell MC, Okunieff P. Hypofractionated stereotactic body radiation therapy (SBRT) for limited hepatic metastases. Int J Radiat Oncol Biol Phys. 2007;67(3):793–8.CrossRefPubMedGoogle Scholar
  16. 16.
    Ambrosino G, Polistina F, Costantin G, Francescon P, Guglielmi R, Zanco P, et al. Image-guided robotic stereotactic radiosurgery for unresectable liver metastases: preliminary results. Anticancer Res. 2009;29(8):3381–4.PubMedGoogle Scholar
  17. 17.
    Lee MT, Kim JJ, Dinniwell R, Brierley J, Lockwood G, Wong R, et al. Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27(10):1585–91.CrossRefGoogle Scholar
  18. 18.
    Rusthoven KE, Kavanagh BD, Cardenes H, Stieber VW, Burri SH, Feigenberg SJ, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27(10):1572–8.CrossRefGoogle Scholar
  19. 19.
    Rule W, Timmerman R, Tong L, Abdulrahman R, Meyer J, Boike T, et al. Phase I dose-escalation study of stereotactic body radiotherapy in patients with hepatic metastases. Ann Surg Oncol. 2011;18(4):1081–7.CrossRefPubMedGoogle Scholar
  20. 20.
    Scorsetti M, Arcangeli S, Tozzi A, Comito T, Alongi F, Navarria P, et al. Is stereotactic body radiation therapy an attractive option for unresectable liver metastases? A preliminary report from a phase 2 trial. Int J Radiat Oncol Biol Phys. 2013;86(2):336–42.CrossRefPubMedGoogle Scholar
  21. 21.
    Scorsetti M, Comito T, Tozzi A, Navarria P, Fogliata A, Clerici E, et al. Final results of a phase II trial for stereotactic body radiation therapy for patients with inoperable liver metastases from colorectal cancer. J Cancer Res Clin Oncol. 2015;141(3):543–53.CrossRefPubMedGoogle Scholar
  22. 22.
    Goodman BD, Mannina EM, Althouse SK, Maluccio MA, Cardenes HR. Long-term safety and efficacy of stereotactic body radiation therapy for hepatic oligometastases. Pract Radiat Oncol. 2015;6(2):86–95.CrossRefPubMedGoogle Scholar
  23. 23.
    Lasley FD, Mannina EM, Johnson CS, Perkins SM, Althouse S, Maluccio M, et al. Treatment variables related to liver toxicity in patients with hepatocellular carcinoma, Child-Pugh class A and B enrolled in a phase 1–2 trial of stereotactic body radiation therapy. Pract Radiat Oncol. 2015;5(5):e443–9.CrossRefPubMedGoogle Scholar
  24. 24.
    Meng M, Wang H, Zeng X, Zhao L, Yuan Z, Wang P, et al. Stereotactic body radiation therapy: a novel treatment modality for inoperable hepatocellular carcinoma. Drug Discov Ther. 2015;9(5):372–9.CrossRefPubMedGoogle Scholar
  25. 25.
    Yamashita H, Onishi H, Murakami N, Matsumoto Y, Matsuo Y, Nomiya T, et al. Survival outcomes after stereotactic body radiotherapy for 79 Japanese patients with hepatocellular carcinoma. J Radiat Res. 2015;56(3):561–7.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Scorsetti M, Comito T, Cozzi L, Clerici E, Tozzi A, Franzese C, et al. The challenge of inoperable hepatocellular carcinoma (HCC): results of a single-institutional experience on stereotactic body radiation therapy (SBRT). J Cancer Res Clin Oncol. 2015;141(7):1301–9.CrossRefPubMedGoogle Scholar
  27. 27.
    Sanuki N, Takeda A, Oku Y, Eriguchi T, Nishimura S, Aoki Y, et al. Influence of liver toxicities on prognosis after stereotactic body radiation therapy for hepatocellular carcinoma. Hepatol Res Off J Jpn Soc Hepatol. 2015;45(5):540–7.CrossRefGoogle Scholar
  28. 28.
    Kimura T, Aikata H, Takahashi S, Takahashi I, Nishibuchi I, Doi Y, et al. Stereotactic body radiotherapy for patients with small hepatocellular carcinoma ineligible for resection or ablation therapies. Hepatol Res Off J Jpn Soc Hepatol. 2015;45(4):378–86.CrossRefGoogle Scholar
  29. 29.
    Huertas A, Baumann AS, Saunier-Kubs F, Salleron J, Oldrini G, Croise-Laurent V, et al. Stereotactic body radiation therapy as an ablative treatment for inoperable hepatocellular carcinoma. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2015;115(2):211–6.CrossRefGoogle Scholar
  30. 30.
    Zhong NB, Lv GM, Chen ZH. Stereotactic body radiotherapy combined with transarterial chemoembolization for huge (>/=10 cm) hepatocellular carcinomas: a clinical study. Mol Clin Oncol. 2014;2(5):839–44.PubMedPubMedCentralGoogle Scholar
  31. 31.
    Takeda A, Sanuki N, Eriguchi T, Kobayashi T, Iwabutchi S, Matsunaga K, et al. Stereotactic ablative body radiotherapy for previously untreated solitary hepatocellular carcinoma. J Gastroenterol Hepatol. 2014;29(2):372–9.CrossRefPubMedGoogle Scholar
  32. 32.
    Lo CH, Huang WY, Lin KT, Lin MJ, Lin TP, Jen YM. Repeated stereotactic ablative radiotherapy using CyberKnife for patients with hepatocellular carcinoma. J Gastroenterol Hepatol. 2014;29(11):1919–25.CrossRefPubMedGoogle Scholar
  33. 33.
    Culleton S, Jiang H, Haddad CR, Kim J, Brierley J, Brade A, et al. Outcomes following definitive stereotactic body radiotherapy for patients with Child-Pugh B or C hepatocellular carcinoma. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2014;111(3):412–7.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  • Harun Badakhshi
    • 1
  1. 1.Department of Radiation OncologyCharité School of MedicineBerlinGermany

Personalised recommendations